RARE Earnings Prediction
The chart below shows how RARE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, RARE sees a -1.65% change in stock price 10 days leading up to the earnings, and a +0.61% change 10 days following the report. On the earnings day itself, the stock moves by +0.33%. This data can give you a slight idea of what to expect for the next quarter's release.
RARE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
139.49M
42.27%
-5.12%
Gross Margin
84.93%
-4.35%
-0.70%
Operating Margin
-94.62%
-36.06%
19.56%
Net Margin
-95.71%
-41.22%
6.93%
EPS
-1.40
-37.22%
-7.89%
No Data Available
RARE Earnings Analysis
Ultragenyx Pharmaceutical Inc. Corporation (RARE.O) Earnings Conference Call
Positive
Quarterly Revenue Surge: $139 million in total revenue for the third quarter of 2024, representing 42% growth versus the prior year quarter.
Crysvita Revenue Breakdown: Crysvita contributed $98 million, including $56 million from North America, $36 million from Latin America and Turkey, and $6 million from Europe.
Latin America Revenue Generation: The company generated over $110 million in revenue this year in Latin America, with the bulk coming from Crysvita.
Reimbursement Process Success: The team has successfully navigated the country-by-country reimbursement process for Evkeezia and Mepssevii, continuing to address unmet need for Crysvita in Turkey.
Substantial Revenue Growth: The company continues to see substantial year-over-year revenue growth as it expands geographic access and further reach more patients with its medicines.
Negative
Quarterly Net Loss: Net loss was $134 million or $1.40 per share for the third quarter, indicating a significant financial setback.
Operating Expenses Overview: Total operating expenses in the third quarter were $271 million, which included R&D expenses of $170 million, reflecting high costs without corresponding revenue growth.
Revenue Growth Slowdown: The company reported $139 million in total revenue for the third quarter of 2024, representing only 42% growth compared to the prior year quarter, indicating slowing growth.
Stock-Based Compensation Impact: Operating expenses included non-cash stock-based compensation of $42 million, which adds to the financial burden without immediate cash benefits.
Increasing Cash Burn: As of September 30, 2024, net cash used in operations was $67 million for the third quarter, and the expectation for 2024 is around $400 million, indicating increasing cash burn.
RARE FAQs
How does RARE typically perform around its earnings report dates?
Is Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
RARE Earning Call Sentiment
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
RARE.O
1.99%Positive
The earnings call presents a mixed sentiment. Financial performance shows strong revenue growth and a solid liquidity position, but high expenses and net loss are concerning. The Q&A section reveals some optimism in product development, but management's unclear responses on certain timelines and trial specifics may raise uncertainties. Overall, the sentiment is neutral to slightly positive, with potential for growth balanced by financial challenges.
